Redwood Pharma has received approval from an Austrian ethics committee for the start of a clinical trial of RP501. This application represents the first of two necessary approvals for the commencement of the clinical trial. The company will now submit the clinical trial application for national approval by the Austrian Federal Office for Safety in Health Care (BASG).

This initiates Redwood Pharma's development efforts towards a CE-marking approval of RP501, the company's novel, first-line treatment for relief of dry eye disease (DED). A CE-marking approval will facilitate the future sale of RP501 as an over-the-counter product within Europe.